Omega-3 and omega-6 polyunsaturated fatty acids in bipolar disorder: A review of biomarker and treatment studies

Journal of Clinical Psychiatry

Volumn 77, Issue 10, 2016, Pages e1301-e1308

  Saunders, Erika F H ^a,b   Ramsden, Christopher E ^c   Sherazy, Mostafa S ^a   Gelenberg, Alan J ^a   Davis, John M ^d   Rapoport, Stanley I ^e  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; FATTY ACID DERIVATIVE; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; BIOLOGICAL MARKER;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CYCLOTHYMIA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; ERYTHROCYTE; FAT INTAKE; HUMAN; HYPOMANIA; META ANALYSIS (TOPIC); OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOM; SYSTEMATIC REVIEW; BLOOD; PSYCHOLOGY; REFERENCE VALUE;

BIOMARKERS; BIPOLAR DISORDER; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES;

EID: 84992708588     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15r09925     Document Type: Review

References (55)

1. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. New York, NY: Oxford University Press; 2007.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
3. Ghaemi SN, Bauer M, Cassidy F, et al; ISBD Diagnostic Guidelines Task Force. Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. Bipolar Disord. 2008;10(1 pt 2):117-128. doi:10.1/j.139-5618.207.056.x PubMed
4. Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453-473. doi:10.1/j.139-5618.209.0726.x PubMed
5. Vieta E, Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 2008;10(1 pt 2):163-178. doi:10.1/j.139-5618.207.0561.x PubMed
6. Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62(12):1322-1330. doi:10.101/archpsyc.62.12.132 PubMed
7. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537. doi:10.101/archpsyc.59.6.530 PubMed
8. Bauer M, Glenn T, Alda M, et al. Comparison of pre-episode and pre-remission states using mood ratings from patients with bipolar disorder. Pharmacopsychiatry. 2011;44(suppl 1):S49-S53. doi:10.105/s-031-1273765 PubMed
9. Bauer M, Glenn T, Rasgon N, et al. Decreasing the minimum length criterion for an episode of hypomania: evaluation using self-reported data from patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2011;261(5):341-347. doi:10.107/s0406-010-0187-x PubMed
10. Bauer M, Glenn T, Grof P, et al. Subsyndromal mood symptoms: a useful concept for maintenance studies of bipolar disorder? Psychopathology. 2010;43(1):1-7. doi:10.159/025957 PubMed
11. Ng F, Mammen OK, Wilting I, et al; International Society for Bipolar Disorders. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559-595. doi:10.1/j.139-5618.209.0737.x PubMed
12. Rapoport SI. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem Neurosci. 2014;5(6):459-467. doi:10.1021/cn5058v PubMed
13. Rapoport SI, Basselin M, Kim HW, et al. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Brain Res Rev. 2009;61(2):185-209. doi:10.1016/j.brainresrev.209.06.03 PubMed
14. Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry. 2002;59(7):592-596. doi:10.101/archpsyc.59.7.592 PubMed
15. Hibbeln JR, Palmer JW, Davis JM. Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness? Biol Psychiatry. 1989;25(7):945-961. doi:10.1016/06-323(89)90274-6 PubMed
16. Allison JH, Stewart MA. Reduced brain inositol in lithium-treated rats. Nat New Biol. 1971;233(43):267-268. doi:10.1038/newbio23267a0 PubMed
17. Hirashima F, Parow AM, Stoll AL, et al. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry. 2004;161(10):1922-1924. doi:10.176/ajp.161.10.192 PubMed
18. Gravaghi C, La Perle KM, Ogrodwski P, et al. Cox-2 expression, PGE(2) and cytokines production are inhibited by endogenously synthesized n-3 PUFAs in inflamed colon of fat-1 mice. J Nutr Biochem. 2011;22(4):360-365. doi:10.1016/j.jnutbio.2010.03.03 PubMed
19. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. 2006;91(2):439-446. doi:10.1210/jc.205-1303 PubMed
20. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids. 2003;38(4):343-352. doi:10.107/s1745-03-1068-y PubMed
21. McNamara RK, Ostrander M, Abplanalp W, et al. Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostaglandins Leukot Essent Fatty Acids. 2006;75(4-5):237-257. doi:10.1016/j.plefa.206.07.09 PubMed
22. Seung Kim HF, Weeber EJ, Sweatt JD, et al. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol Psychiatry. 2001;6(2):246-248. doi:10.1038/sj.mp.40837 PubMed
23. Turnbull T, Cullen-Drill M, Smaldone A. Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: a systematic review. Arch Psychiatr Nurs. 2008;22(5):305-311. doi:10.1016/j.apnu.208.02.01 PubMed
24. Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev. 2008;(2):CD005169. PubMed
25. Chiu CC, Huang SY, Su KP, et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol. 2003;13(2):99-103. doi:10.1016/S0924-97X(02)0130-X PubMed
26. Sublette ME, Bosetti F, DeMar JC, et al. Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disord. 2007;9(7):759-765. doi:10.1/j.139-5618.207.0387.x PubMed
27. Clayton EH, Hanstock TL, Hirneth SJ, et al. Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder. Lipids. 2008;43(11):1031-1038. doi:10.107/s1745-08-324-z PubMed
28. McNamara RK, Jandacek R, Rider T, et al. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J Affect Disord. 2010;126(1-2):303-311. doi:10.1016/j.jad.2010.03.015 PubMed
29. Evans SJ, Kamali M, Prossin AR, et al. Association of plasma ?-3 and ?-6 lipids with burden of disease measures in bipolar subjects. J Psychiatr Res. 2012;46(11):1435-1441. doi:10.1016/j.jpsychires.2012.07.016 PubMed
30. Pomponi M, Janiri L, La Torre G, et al. Plasma levels of n-3 fatty acids in bipolar patients: deficit restricted to DHA. J Psychiatr Res. 2013;47(3):337-342. doi:10.1016/j.jpsychires.2012.1.04 PubMed
31. Saunders EFH, Reider A, Singh G, et al. Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega-3 plasma concentrations are altered by treatment. Bipolar Disord. 2015;17(7):729-742. doi:10.1/bdi.1237 PubMed
32. McNamara RK, Jandacek R, Rider T, et al. Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res. 2008;160(3):285-299. doi:10.1016/j.psychres.207.08.021 PubMed
33. Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry. 2005;66(6):726-729. doi:10.408/JCP.v6n0608 PubMed
34. Sagduyu K, Dokucu ME, Eddy BA, et al. Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J. 2005;4:6. PubMed
35. Wozniak J, Biederman J, Mick E, et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol. 2007;17(6-7):440-447. doi:10.1016/j.euroneuro.206.1.06 PubMed
36. Clayton EH, Hanstock TL, Hirneth SJ, et al. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr. 2009;63(8):1037-1040. doi:10.1038/ejcn.208.81 PubMed
37. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56(5):407-412. doi:10.101/archpsyc.56.5.407 PubMed
38. Chiu CC, Huang SY, Chen CC, et al. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry. 2005;66(12):1613-1614. doi:10.408/JCP.v6n1219b PubMed
39. Keck PE Jr., Mintz J, McElroy SL, et al. Doubleblind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006;60(9):1020-1022. doi:10.1016/j.biopsych.206.03.056 PubMed
40. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry. 2006;188(1):46-50. doi:10.192/bjp.18.1.46 PubMed
41. Frangou S, Lewis M, Wollard J, et al. Preliminary in vivo evidence of increased N-Acetylaspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J Psychopharmacol. 2007;21(4):435-439. doi:10.17/0269810606787 PubMed
42. Gracious BL, Chirieac MC, Costescu S, et al. Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord. 2010;12(2):142-154. doi:10.1/j.139-5618.2010.079.x PubMed
43. Murphy BL, Stoll AL, Harris PQ, et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol. 2012;32(5):699-703. doi:10.1097/JCP.0b013e31826854c PubMed
44. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-Analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73(1):81-86. doi:10.408/JCP.10r06710 PubMed
45. Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res. 1968;9(5):570-579. PubMed
46. Smith QR, Nagura H. Fatty acid uptake and incorporation in brain: studies with the perfusion model. J Mol Neurosci. 2001;16(2-3):167-172, discussion 215-221. doi:10.1385/JMN:16:2-3:167 PubMed
47. Robinson PJ, Noronha J, DeGeorge JJ, et al. A quantitative method for measuring regional in vivo fatty-Acid incorporation into and turnover within brain phospholipids: review and critical analysis. Brain Res Brain Res Rev. 1992;17(3):187-214. doi:10.1016/0165-0173(92)9016-F PubMed
48. Hibbeln JR, Nieminen LR, Blasbalg TL, et al. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr. 2006;83(suppl 6):1483S-1493S. PubMed
49. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry. 2003;160(12):2222-2227. doi:10.176/api.ajp.160.12.2 PubMed
50. Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis. 2007;6(1):21. doi:10.186/1476-51X-6-21 PubMed
51. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-Analysis of randomized controlled trials. J Am Coll Nutr. 2009;28(5):525-542. doi:10.1080/07315724.209.10719785 PubMed
52. Martins JG, Bentsen H, Puri BK. Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated metaanalysis. Mol Psychiatry. 2012;17(12):1144-1149, discussion 1163-1167. doi:10.1038/mp.2012.25 PubMed
53. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-Analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91(3):757-770. doi:10.3945/ajcn.209.28313 PubMed
54. Sublette ME, Ellis SP, Geant AL, et al. Metaanalysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72(12):1577-1584. doi:10.408/JCP.10m0634 PubMed
55. Lin PY, Mischoulon D, Freeman MP, et al. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry. 2012;17(12):1161-1163, author reply 1163-1167. doi:10.1038/mp.2012.1 PubMed